Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Oral GLP-1 approvals and expanded manufacturer programs are likely to shift some demand away from injectables, enhance adherence for patients preferring pills, and introduce new pricing tiers that reflect different distribution models
As the obesity epidemic fuels demand for these new drugs, Lilly looks set to retain its lead, unless a competitor can outpace its innovation and commercialization in the GLP-1 field
This model can help patients get timely consultations, medication reviews, and second opinions without the high costs and delays often associated with traditional healthcare visits
Labonia WD (1995)
US$ 25.18
US$ 23.23
US$ 23.37
US$ 20.01
US$ 21.48
